LACTBL1: A Potential Drug Target and Biomarker for灏?-Lactamase-Like 1-Induced Pediatric Acute Inflammation

Target Name: LACTBL1

NCBI ID: G646262

LACTBL1

Other Name(s): Putative beta-lactamase-like 1 | lactamase beta like 1 | BLML_HUMAN | Lactamase, beta-like 1

LACTBL1: A Potential Drug Target and Biomarker for灏?-Lactamase-Like 1-Induced Pediatric Acute Inflammation

灏?-lactamase (灏?-LO) is a bacterial enzyme that converts 灏?-lactam ring structures to A灏?-sheet structures, thereby producing beta-hydroxy-beta-lactamides (BHLAs) that are pro-inflammatory and can cause tissue damage. In pediatric patients, BHLAs have been observed to cause acute inflammation, including skin infections, pneumonia, and meningitis. The putative beta-lactamase-like 1 (LACTBL1) gene has been identified in pediatric patients with BHLAs, and it has been shown to be involved in the pathogenesis of pediatric acute inflammation. Therefore, targeting LACTBL1 may be a promising strategy for the treatment of pediatric acute inflammation.

LACTBL1 as a Drug Target

LACTBL1 can be considered as a potential drug target due to its unique function in the production of BHLAs. BHLAs have been shown to play a crucial role in the development of inflammatory diseases, including autoimmune diseases, cancer, and neurodegenerative diseases. By inhibiting BHLAs, LACTBL1 may have therapeutic potential in the treatment of inflammatory diseases, including pediatric acute inflammation.

LACTBL1 as a Biomarker

The production of BHLAs by LACTBL1 can be used as a biomarker for the diagnosis and monitoring of pediatric acute inflammation. The level of BHLAs in pediatric patients with acute inflammation can be quantified using techniques such as qRT-PCR, western blotting, and mass spectrometry. If the level of BHLAs is high, it may indicate that a therapeutic intervention is necessary. Additionally, LACTBL1 gene expression levels can be used as a biomarker for tracking the effectiveness of a therapeutic intervention.

Targeting LACTBL1

LACTBL1 has been shown to be involved in the production of BHLAs in pediatric patients with acute inflammation. To target LACTBL1, small molecules with chemical modifications, such as inhibitors or modulators, can be screened to identify compounds that can inhibit BHLAs or modulate LACTBL1 function. One approach is to use inhibitors of LACTBL1-mediated BHLA production, such as those derived from natural products or synthesized compounds. Another approach is to use modulators of LACTBL1 function, such as small molecules that can alter LACTBL1 stability or activity.

Conclusion

In conclusion, LACTBL1 is a potential drug target and biomarker for the treatment of pediatric acute inflammation. The production of BHLAs by LACTBL1 and its involvement in the pathogenesis of pediatric acute inflammation make it a promising target for small molecule inhibitors or modulators. Further research is needed to identify effective compounds that can modulate LACTBL1 function and improve the treatment of pediatric acute inflammation.

Protein Name: Lactamase Beta Like 1

The "LACTBL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LACTBL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets